Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noopur Raje

Showing results (11-20 of 204) with videos related to

Pageof 21
Sort By:
Current Opinion in Oncology|November 1, 2002
Thalidomide and immunomodulatory drugs as cancer therapyNoopur Raje, Kenneth C Anderson
Future Oncology (London, England)|March 13, 2010
Novel therapeutic targets for multiple myelomaAnuj Mahindra, Diana Cirstea, Noopur Raje
Hematology. American Society of Hematology. Education Program|December 5, 2025
Choosing the optimal maintenance strategy in multiple myelomaBenjamin Puliafito, Diana Cirstea, Noopur Raje
Cancer Journal (Sudbury, Mass.)|December 17, 2009
Future novel single agent and combination therapiesDiana Cirstea, Sonia Vallet, Noopur Raje
Clinical Advances in Hematology & Oncology : H&O|October 18, 2012
Clinical trials of bisphosphonates in multiple myelomaAnuj Mahindra, Samantha Pozzi, Noopur Raje
Cancer Biology & Therapy|February 25, 2012
Cyclin dependent kinases in cancer: potential for therapeutic interventionMiriam Canavese, Loredana Santo, Noopur Raje
Expert Review of Anticancer Therapy|October 6, 2006
Therapeutic use of immunomodulatory drugs in the treatment of multiple myelomaNoopur Raje, Teru Hideshima, Kenneth C Anderson
Dentistry Journal|May 19, 2019
Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet OncologyNoopur Raje, Evangelos Terpos, Danielle D Jandial
The New England Journal of Medicine|July 18, 2019
Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma. ReplyNoopur Raje, Kristen Hege, James N Kochenderfer
Seminars in Oncology|November 29, 2015
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human CancersLoredana Santo, Ka Tat Siu, Noopur Raje
Pageof 21

Showing results (11-20 of 204) with videos related to

Sort By:
Pageof 21
Current Opinion in Oncology|November 1, 2002
Thalidomide and immunomodulatory drugs as cancer therapyNoopur Raje, Kenneth C Anderson
Future Oncology (London, England)|March 13, 2010
Novel therapeutic targets for multiple myelomaAnuj Mahindra, Diana Cirstea, Noopur Raje
Hematology. American Society of Hematology. Education Program|December 5, 2025
Choosing the optimal maintenance strategy in multiple myelomaBenjamin Puliafito, Diana Cirstea, Noopur Raje
Cancer Journal (Sudbury, Mass.)|December 17, 2009
Future novel single agent and combination therapiesDiana Cirstea, Sonia Vallet, Noopur Raje
Clinical Advances in Hematology & Oncology : H&O|October 18, 2012
Clinical trials of bisphosphonates in multiple myelomaAnuj Mahindra, Samantha Pozzi, Noopur Raje
Cancer Biology & Therapy|February 25, 2012
Cyclin dependent kinases in cancer: potential for therapeutic interventionMiriam Canavese, Loredana Santo, Noopur Raje
Expert Review of Anticancer Therapy|October 6, 2006
Therapeutic use of immunomodulatory drugs in the treatment of multiple myelomaNoopur Raje, Teru Hideshima, Kenneth C Anderson
Dentistry Journal|May 19, 2019
Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet OncologyNoopur Raje, Evangelos Terpos, Danielle D Jandial
The New England Journal of Medicine|July 18, 2019
Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma. ReplyNoopur Raje, Kristen Hege, James N Kochenderfer
Seminars in Oncology|November 29, 2015
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human CancersLoredana Santo, Ka Tat Siu, Noopur Raje
Pageof 21